How to Reduce Expired Stock Losses in Indian Pharmacies

every pharmacy owner knows the number. they just won't say it out loud.

I have a question I like to ask pharmacy owners: how much do you lose to expired stock every year? The answer is always some version of "not much" or "we manage it well" or, my favourite, a hand wave and a change of subject. These are people who can tell you their daily sales to the rupee, who know exactly which doctor sends the most prescriptions, who can recite their top 20 SKUs by margin from memory. But the expiry loss number? Vague. Always vague.

Then you pull the write-off register. You count the destruction records (the ones filed under Form 29 for scheduled drugs, and the informal ones for everything else). You total up the distributor returns that got rejected because they were submitted two weeks after the return window closed. You add the stock that was discovered expired during a shelf check and quietly disposed of without paperwork. And the real number turns out to be three to five times whatever the owner quoted.

For a pharmacy doing ₹8-12 lakhs a month in revenue — which is a fairly typical mid-size pharmacy in a Tier 1 or Tier 2 city — the annual expiry loss is usually ₹1.2 to 2.5 lakhs. That's 10-20% of net profit. Not of revenue. Of profit. Gone. Not to competition, not to bad debts, not to theft (which gets far more attention). Just to medicine sitting on a shelf past its date.

The reason this number stays hidden is that it accumulates in small amounts. One strip here, three bottles there, a box of insulin pens that needed cold chain and didn't get it. Each individual instance feels minor. The aggregate is not minor at all.

why pharmacies lose more than other retail businesses to expiry

Grocery stores lose to expiry too. Dairy shops, bakeries, supermarkets — they all have waste. But pharmacies have it structurally worse, and it's worth understanding why, because the structural reasons point directly to the structural fixes.

A 200 square foot pharmacy — and most Indian pharmacies are small — carries 2,500 to 4,000 unique SKUs. A grocery store of the same size carries maybe 800 to 1,200. This is the first problem. More SKUs means less visual attention per item, more shelf positions to check, and more places where a slow-moving product can sit unnoticed for months. The probability that any given SKU gets overlooked during a manual shelf check scales linearly with SKU count. Pharmacies have 3x the SKU density of grocery, which means roughly 3x the probability of any specific item being missed.

The second structural problem is long shelf life creating false security. Most pharmaceutical products carry 18 to 36 month shelf lives. Nobody panics about a strip of Augmentin with 15 months remaining. It doesn't feel urgent. But that same strip, purchased in bulk during a distributor scheme in March, sits behind faster-moving stock for eight months. By November it has seven months left, which still sounds fine — except the distributor's return window closed in September, and the actual sell-through rate at this pharmacy means the remaining stock won't move before expiry. The long shelf life didn't protect it. It just delayed the recognition of the problem past the point where it could be fixed cheaply.

The third structural problem is scheme-driven overstocking, and this one is uniquely Indian. Pharmaceutical distribution in India runs on trade schemes that incentivise purchase volume over consumption rate. "Buy 100, get 15 free" sounds like a 15% margin boost. What it actually means is that if your monthly demand is 80 units, you just acquired 115 units — a 44-day supply when you only needed a 30-day supply. The 35-unit surplus has the same expiry date as the purchased stock. The demand doesn't increase because you got a deal. You just shifted the financial risk from the distributor's balance sheet to your shelf.

the five specific places where the money disappears

These aren't abstract categories. They're physical locations and moments in time where a recoverable situation becomes a loss.

The back of the shelf. Pharmacy shelves run 60 to 90 centimetres deep. New stock goes in front because the helper receives it and places it in the most accessible spot. Yesterday's stock gets pushed deeper. Last week's stock is now behind two layers of newer product. Nobody sees it until someone does a deep shelf check, which in most pharmacies happens sporadically if it happens at all. By the time the buried stock surfaces, it's either expired or has days remaining. This single pattern — new stock forward, old stock backward — is the largest single source of pharmacy expiry loss. The fix is to reverse it: new stock goes behind, old stock stays in front. It costs 10 extra seconds per item during stocking. It's the most boring intervention in pharmacy management, and it's also the most effective.

The distributor return window, missed. Every distributor has a return policy for near-expiry stock. The typical window is 3 to 6 months before expiry for full credit. Some tighten it to 4 months. The maths of this are unforgiving: a strip that could have been returned in September for ₹120 in credit is found expired in January and becomes a ₹120 write-off. The difference between the two outcomes is not effort or skill. It's awareness. Knowing the stock exists, knowing the return window, and acting before it closes. Most pharmacies discover returnable stock after the window has passed. Not by weeks — usually by days. The near-miss quality of this particular loss is what makes it so frustrating once you start measuring it.

Scheme-induced surplus. I mentioned this above but the mechanics are worth walking through in detail. The typical scheme: buy ₹10,000 worth of Brand X, get ₹1,500 in free goods. Your actual monthly demand for Brand X is ₹8,000. To hit the scheme threshold you overshoot by ₹2,000 in purchases, and then you receive ₹1,500 in free goods on top. That ₹3,500 surplus — the ₹2,000 you bought beyond demand plus the ₹1,500 free stock — sits on your shelf until either demand absorbs it or time doesn't. For fast-moving products, demand usually catches up. For the slow-moving variants that often get bundled into scheme offers (because the brand is trying to push them), it doesn't. One calculation before accepting any scheme tells you what you need to know: scheme quantity divided by monthly demand. If the answer is more than two months of supply, the scheme is not a deal. It's a slow-motion write-off wearing the disguise of a margin boost.

Slow movers accumulating quietly. Every pharmacy has 200 to 400 SKUs that sell fewer than 5 units a month. The specific dermatological preparation that one doctor prescribes. The paediatric suspension that moves two bottles every three months. The niche supplement. These are disproportionately expensive (specialist drugs carry ₹200-800 unit costs, not ₹20-50 like common OTC strips), and they're disproportionately likely to expire. They occupy shelf positions for months without anyone particularly noticing, because they don't appear on any fast-moving report and they don't trigger any reorder alert. They just sit. The classification is straightforward — fast movers (20+ units/month), medium movers (5-19), slow movers (under 5) — and the ordering rule for slow movers should be equally straightforward: order against prescriptions, keep maximum two months of stock, and accept a slightly higher stockout risk in exchange for a much lower expiry risk.

Schedule H1 drugs expiring. Expired H1 drugs cost you the product value plus the compliance overhead. The Drugs and Cosmetics Act requires Form 29 documentation for destruction of expired scheduled drugs. A Drug Inspector finding expired H1 stock on your shelf can issue a show-cause notice. Repeated findings can initiate license suspension proceedings. The financial loss is compounded by the legal exposure, the documentation time, the potential legal consultation fees, and the reputational effect during your next license renewal review. H1 stock warrants the tightest monitoring — 9-month alerts for drugs with 24-month shelf life, 6-month alerts for those with 12-month shelf life — because the cost of getting it wrong extends well beyond the product value.

the weekly check system that works (and why the current one doesn't)

Most pharmacies do "expiry checks" that consist of a staff member scanning the front-facing stock in each category and pulling forward anything that looks close. This catches maybe 30% of near-expiry items, because it only inspects the front-facing layer of shelves that are three layers deep, in a store with thousands of SKUs competing for a finite amount of visual attention.

A systematic rotation works better. Week 1: controlled substances and high-value items (anything over ₹500 per unit). Check every unit, not just front-facing. This is your highest-risk, highest-cost category, and it has the worst compliance consequences. Week 2: antibiotics, cardiac, and diabetes medications — the high-volume categories most affected by scheme surplus. Week 3: OTC, supplements, and dermatological — low compliance risk, but where slow movers quietly accumulate. Week 4: everything else, plus a full review of items flagged in weeks 1-3 that need return processing.

Two to three hours per week for a pharmacy with 3,000 SKUs. Annual cost in staff time: ₹35,000-45,000. Annual waste prevented: ₹80,000-1,50,000, depending on your current baseline. The return on investment is 2-3x before accounting for the compliance benefits.

three distributor conversations that pay for themselves

Extended return windows. If your distributor gives 3 months, negotiate for 6. Your leverage: longer windows mean you can consolidate more purchases with this distributor instead of splitting volume across competitors to reduce risk. Most distributors will agree for reliable, regularly ordering accounts.

Smaller, more frequent deliveries. Bi-weekly instead of monthly. The per-delivery cost may be marginally higher. A 15-day supply generates less expiry waste than a 30-day supply. The waste reduction math usually dominates the delivery cost increase substantially.

Scheme substitution rights. When a scheme includes free goods, ask to substitute slow-moving variants for faster-moving ones. Many companies allow this through the stockist if the total scheme value is maintained. This single negotiation point — swapping the slow-moving free goods for ones you'll actually sell — can prevent ₹5,000-15,000 in annual scheme-related expiry.

what to do when stock is going to expire regardless

Three months out: contact nearby clinics and hospitals. Many will purchase near-expiry stock at a discount if their consumption will exhaust it before expiry. This is common practice and straightforward legal.

Two months out: circulate to other pharmacists. Pharmacy owner WhatsApp groups in every locality trade near-expiry stock routinely. What's slow-moving at your location might be fast-moving at a pharmacy near a hospital with a different prescribing pattern.

One month out: return to distributor if within window. If outside the window, prepare Form 29 documentation for destruction.

Expired: do not sell. Section 18(c) of the Drugs and Cosmetics Act. Imprisonment and license cancellation. The financial incentive to sell expired stock is always small. The downside risk is existential.

the arithmetic

A pharmacy doing ₹10 lakhs monthly, currently losing ₹1.8 lakhs per year to expiry, can realistically bring that down to ₹50,000-70,000 through systematic FEFO rotation, velocity-based ordering, scheme discipline, and a structured weekly check cycle. The net improvement is ₹1.1-1.3 lakhs in recovered margin. The cost is labour time — roughly ₹40,000 per year — and process discipline. No capital expenditure. No new equipment. Just a different way of paying attention to inventory that's already sitting on your shelves.

ShelfLifePro gives Indian pharmacies batch-level expiry tracking, automated alerts before return windows close, and FEFO-first billing. See what it catches in your first week.